2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1482

Temporomandibular Pain in Patients with Juvenile Idiopathic Arthritis
Abstract Number: 2649

Test-Retest Reliability of the 5-Item Compliance Questionnaire Rheumatology and Factors Influencing Its Assessment of Adherence in Patients with Rheumatoid Arthritis
Abstract Number: 1147

TGFß1 Blocks Chondrocyte Hypertrophy and Increases Cell Viability in Cultured Cartilage Explants but Does Not Protect Against Proteoglycan Loss
Abstract Number: 2695

Th17 Cell Related Cytokines and Microarray Expression Profiles in Patients with Early Rheumatoid Arthritis
Abstract Number: 1156

Th17 Cytokines Regulate Osteoclastogenesis in Rheumatoid Arthritis
Abstract Number: 994

Th17/Tfh Cell Predict Disease Severity in Rheumatoid Arthritis Patients Receiving TNF Inhibitor Therapy
Abstract Number: 2608

The “Rheumatoid Arthritis Impact of Disease”� Score Correlates with Other Patient Reported Outcomes and with Disease Activity Scores in Patients with RA and Its Patient Acceptable Symptom State Is More Stringent Than DAS28-Remission
Abstract Number: 305

The “Sleeve Sign”� in Dermatomyositis
Abstract Number: 2406

The 2011 Fibromyalgia (FM) Criteria Are Helpful in Identifying Central Sensitization in Knee Osteoarthritis
Abstract Number: 2290

The 2011 Fibromyalgia (FM) Survey Criteria Are a Surrogate Measure of Pain Centralization
Abstract Number: 2857

The 8-Year Retention Rate of the First TNF-Inhibitor in the Treatment of Spondyloarthropathies: Real-Life Data from Three Local Registries
Abstract Number: 96

The ABCG2 polymorphism Is Associated with Hyperuricemia in a Community-Based Korean Cohort
Abstract Number: 2176

The Ability of Recombinant Domain I of Beta-2-Glycoprotein I to Inhibit Lupus Anticoagulant Effect of IgG from Patients with APS Is Enhanced By Pegylation
Abstract Number: 2396

The Absence of Symptom in Subjects with Advanced Knee OA
Abstract Number: 1149

The Active Metabolite of Fostamatinib, R406, Only Decreases the Inflammation-Driven Extracellular Matrix Turnover of the Joint at High Concentrations Ex Vivo

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].